



Assessing the impact of the COVID-19 pandemic on patient advocacy and support organisations

Professor Matthew Peters
Global Lung Cancer Coalition
Australia



DISCLOSURES

Commercial Interest	Relationship(s)
Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, Takeda	The Global Lung Cancer Coalition (GLCC) has received no specific funding for this project. The GLCC receives support from a number of Sustaining Partners, commercial companies that want to demonstrate their commitment to lung cancer patients by helping the GLCC promote global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care.

Rationale

wclc2020.IASLC.com | [#WCLC20](https://twitter.com/WCLC20)

CONQUERING THORACIC CANCERS WORLDWIDE



GLOBAL LUNG CANCER
COALITION

The Global Lung Cancer Coalition (GLCC) is a partnership of 40 patient organisations across 29 countries

Our members play an essential role in supporting patients every day, and we knew they were being called on for increased support as the COVID-19 pandemic hit

The GLCC wanted to understand the pandemic's impact on our members, identify challenges they were experiencing, and any common themes or differences

Methodology

wclc2020.IASLC.com | #WCLC20

CONQUERING THORACIC CANCERS WORLDWIDE



A multinational steering group designed a 15 question survey



Questions were based on four themes: demand from patients, patient needs, changes to services offered, and impact on organisation's finances



The online survey was sent to all GLCC members and was open for three weeks between April and May 2020

23 responses

wclc2020.IASLC.com | #WCLC20

CONQUERING THORACIC CANCERS WORLDWIDE



22 organisations
from 21 countries
and one pan-
European
organisation
responded

Key findings

wclc2020.IASLC.com | #WCLC20

CONQUERING THORACIC CANCERS WORLDWIDE



Increased requests from patients via **telephone, email, Facebook** and **website**
Frequent questions on **risk of contracting COVID-19** and **implications of treatment delays** because of COVID-19




2 in 3 responding organisations had closed face-to-face services. But **86%** had introduced new online or digital services



67% of organisations have seen a **decrease** in their **income**



Only **five** organisations' **national or regional governments** had offered any **financial support** to charities



Members' worries included how to **provide same level of services** as pre-pandemic, how to keep **employing staff**, and even their **survival** as an organisation

Takeaway and next steps

wclc2020.IASLC.com | #WCLC20

CONQUERING THORACIC CANCERS WORLDWIDE

Patient organisations are providing more support during the pandemic, and many are doing so with decreased resources

The GLCC is planning two further surveys to understand the continuing impact of COVID-19 on patient organisations (Winter 2020 and Spring 2021)